Bioanalytical Sample Shipment and Management Process Flow: Translational and Clinical Services

Overcoming ADMET Challenges in Drug Discovery: Antibiotics and Prodrugs | DMPK Unravelled #2

Syngene 32nd Annual General Meeting- July 23, 2025

Syngene Annual Report 2024–25: INNOVATING REACH

The Syngene Advantage: Accelerating Progress Through Integrated Technology Transfer

Building a Better Tomorrow: Syngene’s ESG Impact

Thriving in a Connected World: The Power of Strategic Outsourcing

Drug metabolism and pharmacokinetics at Syngene | Vishwottam Kandikere, Ph.D, Head of DMPK

Syngene: Your Partner in Building a Healthier World

Syngene's Analytical Development Facility

ED and CFO Sibaji Biswas on US Biosecure Act and its impact on Indian pharma companies

Syngene 31th Annual General Meeting - July 24, 2024

Syngene Annual Report 2024

Syngene Corporate Film - 2024

Syngene's MD and CEO, Jonathan Hunt, on Q4 and FY24 results

Syngene's CFO and Executive Director, Sibaji Biswas, on Q4 and FY24 results

Operational Excellence Expo FY 24

Syngene's Small Molecule non-GMP Facility

Syngene Corporate Video 2024

Syngene's API Mangalore Manufacturing Plant- MSEZ #API #GMP #usfda

Syngene's High Potent API Manufacturing facility

State-of-the-art Quality Control Biologics Lab | Syngene

Syngene’s growth story: CRO to global CRDMO in 30 years

Small Molecule cGMP Manufacturing Facility at Bangalore | Syngene

End-to-end Oligonucleotides services: Early Discovery to cGMP Manufacturing | Syngene

Celebrating our ‘long service heroes’ on our 30th anniversary: The heart of our company | Part 2

Celebrating our ‘long service heroes’ on our 30th anniversary: The heart of our company | Part 1

Syngene: Your partner in building a healthier world

How Syngene supports women in science #womeninscienceday #WomenInSTEM #csr

Empowering communities through healthcare and education

Sibaji Biswas - Our CFO on Q2FY24 & First-half FY24 results #syngene #financialresults

Jonathan Hunt - MD & CEO on Q2FY24 & First-half FY24 results #syngene #financialresults

Ensure regulatory-grade Safety profile of your lead compound | In Vitro & Genetic Toxicology #shorts

Full-stack In vitro & Genetic Toxicology services | Screening to IND submission

Groundbreaking Ceremony in Genome Valley, Hyderabad 2023

Syngene 30th Annual General Meeting- July 26, 2023

Syngene Annual Report 2023: Exceptional Partnerships, Dynamic Growth

Meet us at BIO 2023 - Booth no: 265, Hall A

World Environment Day - Message from our COO Dr. Mahesh Bhagat

Year-end reflections/Outlook for the year ahead: Sibaji Biswas

Year-end reflections/Outlook for the year ahead: Jonathan Hunt

Rapid Discovery! Accelerate drug discovery from hit ID to the clinic

Syngene at the Animal Health, Nutrition, and Technology Innovation Europe Summit 2023

Syngene's Sterile fill finish facility

Life at Syngene - Spotlight on Computational & Data Sciences with Dr. Achintya Das

Life at Syngene- Spotlight on Discovery Biology with Dr. Jayashree Aiyar

Thank you for connecting with Syngene at CPHI Frankfurt 2022

Syngene CFO Sibaji Biswas on Q2FY23 results

Syngene MD & CEO, Jonathan Hunt on the Q2FY23 financial results

Syngene CSR: Training on management of Malnutrition in local communities

Celebrating 75 years of Indian Independence at Syngene

Syngene 29th Annual General Meeting- July 20, 2022

Syngene Annual Report 2021-22

Everything you need to know: In Silico Drug Target Assessment Services #drugdiscovery

Life at Syngene: Spotlight on Human Pharmacology Unit with Dr. Anil

Syngene FY22 Highlights

Drug Repurposing-Perspective on an emerging pharmaceutical solution -Fireside Chat 10

Creating the RIGHT toxicology strategy: Learning from the past to shape the future -Fireside chat 11

The year gone by and outlook for FY23: Jonathan Hunt

Syngene’s Early-Stage Process Research Lab (Drug Discovery)